Table 3 |
||||||
|
Principle outcomes of the constant effect analyses* |
||||||
|
Comparator |
||||||
|
Treatment |
No drug treatment |
Rivastigmine |
Donepezil |
Galantamine |
||
|
|
||||||
|
1–4 mg |
6–12 mg |
5 mg |
10 mg |
16 mg |
||
|
|
||||||
|
Rivastigmine |
||||||
|
1–4 mg |
3.0%** $2,880† $224,222¶ |
|||||
|
6–12 mg |
5.8% $514 $36,161 |
3.0% -$2,370 Dominant |
||||
|
Donepezil |
||||||
|
5 mg |
6.6% $1,032 $36,161 |
3.7% -$1,849 Dominant |
0.8% $522 $158,875 |
|||
|
10 mg |
9.5% -$811 Dominant |
6.7% -$3,692 Dominant |
3.9% -$1,321 Dominant |
3.1% -$1,843 Dominant |
||
|
Galantamine |
||||||
|
16 mg |
10.2% -$1,134 Dominant |
7.5% -$4,015 Dominant |
4.6% -$1,644 Dominant |
3.9% -$2,166 Dominant |
0.8% -$323 Dominant |
|
|
24 mg |
10.3% -$1,366 Dominant |
7.6% -$4,246 Dominant |
4.7% -$1,876 Dominant |
4.0% -$2,398 Dominant |
0.9% -$555 Dominant |
0.1% -$232 Dominant |
|
|
||||||
|
* for each drug treatment in the rows the comparison is made relative to the approach in the column ** percent reduction in time spent requiring FTC † net costs ¶ incremental cost per QALY gained |
||||||
|
Caro et al. BMC Geriatrics 2003 3:6 doi:10.1186/1471-2318-3-6 |
||||||
